Business
Beyond Air® Announces Participation at Upcoming Virtual Investor Conferences in May 2021
GARDEN CITY, N.Y., April 14, 2021 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused
About this update from Beyond Air, Inc.
[{"type":"text","content":"GARDEN CITY, N.Y., April 14, 2021 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and gaseous NO (gNO) for the treatment of solid tumors, today announced that Steve Lisi, Chairman and Chief Executive Officer of Beyond Air, is scheduled to participate in two upcoming virtual investor conferences in May 2021. Details for Upcoming Conferences: Event:7th Annual Truist Securities 2021 Life Sciences SummitDate and Time: May 4-5, 2021Participation: Management will participate in a virtual fireside chat that is scheduled for Tuesday, May 4th at 11:20 AM ET, as well as 1-on-1 meetings virtually Event:Oppenheimer MedTech SummitDate and Time:May 26, 2021Participation:Management will be available for 1-on-1 meetings virtually Please contact your representative at either Truist Securities or Oppenheimer to schedule a virtual one-on-one meeting with Beyond Air during the respective conference. About Beyond Air, Inc.Beyond Air, Inc. is a clinical-stage medical device and biopharmaceutical company developing a revolutionary NO Generator and Delivery System, LungFit®, that uses NO generated from ambient air to deliver precise amounts of NO to the lungs for the potential treatment of a variety of pulmonary diseases. LungFit® can generate up to 400 ppm of NO, for delivery either continuously or for a fixed amount of time and has the ability to either titrate dose on demand or maintain a constant dose. The Company is currently applying its therapeutic expertise to develop treatments for pulmonary hypertension in various settings, in addition to treatments for respiratory tract infections that are not effectively addressed with current standards of care. Beyond Air is currently advancing its revolutionary LungFit® for clinical trials for the treatment of severe lung infections such as SARS-CoV-2 and nontuberculous mycobacteria (NTM). Additionally, Beyond Air is using ultra-high concentrations of NO with a proprietary delivery system to target certain solid tumors in the pre-clinical setting. For more information, visit www.beyondair.net. Forward Looking StatementsThis press release contains “forward-looking statements...